Fucidol®-B cream
For Inflammatory dermatoses

Fucidol®-B cream topical preparation contains two active components:

  • Fusidic acid which is glycopeptide compound, that exerts potent topical antibacterial action.
  • When applied topically, fusidic acid is effective against staphylococci, streptococci, cornyebacteria, neisseria, certain clostridia and bacteroides.
  • The antibacterial activity of fusidic acid is not diminished by betamethasone.
  • Betamethasone is a corticosteroid compound used topically for its activity as anti-inflammatory and antipruritic agent.
  • Fucidol®-B cream is effective in inflammatory dermatoses accompanied by bacterial infection, even refractory condition can often be treated successfully.

Each 100 gram of  Fucidol®-B cream contains :

  • Fusidic acid                              2g
  • Betamethasone( as valerate) 0.1g
  • Fucidol®-B cream is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur.
  • Inflammatory dermatoses include atopic eczema,discoid eczema, stasis eczema, seborrhoeic dermatitis, contact dermatitis, lichen simple chronicus, psoriasis and discoid lupus erythrematosus.
  • Hypersensitivity to any component of the product.
  • Topical corticosteroids are contraindicated in viral, tuberculousis, fungal skin infections, perioral dermatitis, acne rosacea and ulcerative condition.
  • Topical steroid should not be administered extensively in pregnancy as fetal abnormalities have been seen in animal studies due to systemic absorption. 
  • This preparation is generally well tolerated, side effect  are infrequent and mild in nature.
  • As with other topical corticosteroids , prolong and intensive administration may cause local atrophic changes of the skin, thinning and dilatation of the superficial blood vessels, especially when occlusive dressing is used or when skin folds are involved.
  • Hypersensitivity reactions have rarely occurred.
  • Glaucoma might be the result if the preparation enters the eye.


  • Significant systemic reactions resulting from improper use or accidental overdose (such as in children) should be managed by taking the necessary supportive measures.

Uncovered lesions:

  • Fucidol®-B cream applied 2 -3 times daily. 

Covered lesions:

  • less frequent application may be adequate.

¤ The duration of therapy depends on the indication and response of the patient or as directed by the physician. 

  • Long term continuous therapy should be avoided, particularly on the face, on flexure, intertrigenousareas and in infant and children.
  • This medicament should not be applied to broken skin or open wound.
  • Caution should be observed to avoid any contact of this medicament with the eyes.
  • Tube of 15 g cream .
  • Store below 30 °C.